PALO ALTO, Calif., Aug. 9, 2017 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) today announced it has signed an agreement with Bionix® Radiation Therapy to distribute Bionix brachytherapy applicators. Varian will market the Bionix Esophageal Applicator (E-App™) and the Anorectal Applicator (AR-1™) in North America.
The E-App is a disposable brachytherapy applicator, and is designed specifically for the treatment of upper GI cancers. The E-App features five independently operable balloons that maintain the central position of the source catheter in both straight and curved anatomy, allowing for closer proximity of the target to the source, while maintaining distance from healthy tissue.
The AR-1 is a disposable brachytherapy applicator designed specifically for the treatment of anal and rectal cancers. The dual balloon design of the AR-1 allows exophytic tumors to press closer to the source catheter. This creates the ability to deliver a very high dose to the tumor, while sparing healthy tissue.
"We are pleased to partner with Bionix to provide cancer specialists with an expanded portfolio of innovative brachytherapy applicators," said Thomas Pollatz, Director of Brachytherapy Marketing at Varian Medical Systems. "The Bionix AR-1 and E-App applicators are complementary to Varian's current applicator family and increase treatment options aimed at providing the best treatment solution for the patient."
For more information on Varian's brachytherapy portfolio, visit https://www.varian.com/oncology/solutions/brachytherapy.
About Varian Medical Systems
Varian Medical Systems focuses energy on saving lives and is the world's leading manufacturer of medical devices and software for treating and managing cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,600 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
Varian Medical Systems
+1 (650) 424-5630
SOURCE Varian Medical Systems